annual EBIT:
$10.43B+$1.95B(+22.91%)Summary
- As of today (April 13, 2025), AZN annual earnings before interest & taxes is $10.43 billion, with the most recent change of +$1.95 billion (+22.91%) on December 31, 2024.
- During the last 3 years, AZN annual EBIT has risen by +$9.42 billion (+931.95%).
- AZN annual EBIT is now -18.73% below its all-time high of $12.84 billion, reached on December 31, 2011.
Performance
AZN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$2.10B-$190.00M(-8.32%)Summary
- As of today (April 13, 2025), AZN quarterly earnings before interest & taxes is $2.10 billion, with the most recent change of -$190.00 million (-8.32%) on December 31, 2024.
- Over the past year, AZN quarterly EBIT has stayed the same.
- AZN quarterly EBIT is now -53.67% below its all-time high of $4.52 billion, reached on March 31, 1999.
Performance
AZN quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
$10.43B+$790.00M(+8.19%)Summary
- As of today (April 13, 2025), AZN TTM earnings before interest & taxes is $10.43 billion, with the most recent change of +$790.00 million (+8.19%) on December 31, 2024.
- Over the past year, AZN TTM EBIT has stayed the same.
- AZN TTM EBIT is now -23.25% below its all-time high of $13.59 billion, reached on September 30, 2011.
Performance
AZN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AZN EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.9% | 0.0% | 0.0% |
| 3 y3 years | +932.0% | +275.4% | +2021.4% |
| 5 y5 years | +253.7% | +275.4% | +2021.4% |
AZN EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +932.0% | -34.8% | +275.4% | at high | +2021.4% |
| 5 y | 5-year | at high | +932.0% | -34.8% | +225.8% | at high | +2021.4% |
| alltime | all time | -18.7% | +2280.2% | -53.7% | +143.4% | -23.3% | +2021.4% |
AstraZeneca EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $10.43B(+22.9%) | $2.10B(-8.3%) | $10.43B(+8.2%) |
| Sep 2024 | - | $2.29B(-19.5%) | $9.64B(+2.6%) |
| Jun 2024 | - | $2.84B(-11.6%) | $9.40B(+3.5%) |
| Mar 2024 | - | $3.21B(+146.2%) | $9.08B(+6.9%) |
| Dec 2023 | $8.49B(+121.6%) | $1.30B(-36.2%) | $8.49B(+2.2%) |
| Sep 2023 | - | $2.04B(-18.9%) | $8.31B(+10.4%) |
| Jun 2023 | - | $2.52B(-4.1%) | $7.53B(+35.2%) |
| Mar 2023 | - | $2.63B(+134.1%) | $5.57B(+45.4%) |
| Dec 2022 | $3.83B(+278.9%) | $1.12B(-11.0%) | $3.83B(+60.7%) |
| Sep 2022 | - | $1.26B(+126.0%) | $2.38B(-539.0%) |
| Jun 2022 | - | $558.00M(-37.2%) | -$543.00M(+4836.4%) |
| Mar 2022 | - | $889.00M(-374.4%) | -$11.00M(-101.1%) |
| Dec 2021 | $1.01B(-80.5%) | -$324.00M(-80.6%) | $1.01B(-63.8%) |
| Sep 2021 | - | -$1.67B(-252.8%) | $2.79B(-50.5%) |
| Jun 2021 | - | $1.09B(-43.0%) | $5.63B(-3.4%) |
| Mar 2021 | - | $1.91B(+31.4%) | $5.83B(+12.4%) |
| Dec 2020 | $5.19B(+75.9%) | $1.45B(+23.5%) | $5.19B(+20.8%) |
| Sep 2020 | - | $1.18B(-8.8%) | $4.29B(+10.7%) |
| Jun 2020 | - | $1.29B(+1.8%) | $3.88B(+25.5%) |
| Mar 2020 | - | $1.27B(+125.8%) | $3.09B(+4.8%) |
| Dec 2019 | $2.95B(-12.2%) | $561.00M(-26.4%) | $2.95B(-13.3%) |
| Sep 2019 | - | $762.00M(+51.8%) | $3.40B(-2.3%) |
| Jun 2019 | - | $502.00M(-55.4%) | $3.48B(-7.6%) |
| Mar 2019 | - | $1.13B(+10.9%) | $3.77B(+12.1%) |
| Dec 2018 | $3.36B(-6.4%) | $1.01B(+20.6%) | $3.36B(+15.3%) |
| Sep 2018 | - | $841.00M(+6.9%) | $2.91B(-10.0%) |
| Jun 2018 | - | $787.00M(+9.8%) | $3.24B(-4.5%) |
| Mar 2018 | - | $717.00M(+26.2%) | $3.39B(-5.7%) |
| Dec 2017 | $3.59B(-27.1%) | $568.00M(-51.2%) | $3.59B(-35.3%) |
| Sep 2017 | - | $1.16B(+23.8%) | $5.55B(+2.5%) |
| Jun 2017 | - | $940.00M(+2.0%) | $5.42B(+13.1%) |
| Mar 2017 | - | $922.00M(-63.5%) | $4.79B(-2.6%) |
| Dec 2016 | $4.92B(+19.7%) | $2.53B(+145.2%) | $4.92B(+42.6%) |
| Sep 2016 | - | $1.03B(+230.4%) | $3.45B(-4.1%) |
| Jun 2016 | - | $312.00M(-70.2%) | $3.60B(-14.7%) |
| Mar 2016 | - | $1.05B(-0.9%) | $4.22B(+2.7%) |
| Dec 2015 | $4.11B(+86.0%) | $1.06B(-10.1%) | $4.11B(+50.5%) |
| Sep 2015 | - | $1.18B(+26.0%) | $2.73B(+29.3%) |
| Jun 2015 | - | $934.00M(-0.5%) | $2.11B(-8.1%) |
| Mar 2015 | - | $939.00M(-393.4%) | $2.30B(+4.0%) |
| Dec 2014 | $2.21B(-41.2%) | -$320.00M(-157.3%) | $2.21B(+13.4%) |
| Sep 2014 | - | $558.00M(-50.1%) | $1.95B(-37.4%) |
| Jun 2014 | - | $1.12B(+31.5%) | $3.11B(-2.8%) |
| Mar 2014 | - | $851.00M(-246.5%) | $3.20B(-15.1%) |
| Dec 2013 | $3.76B(-54.0%) | -$581.00M(-133.8%) | $3.77B(-40.2%) |
| Sep 2013 | - | $1.72B(+42.5%) | $6.30B(-6.6%) |
| Jun 2013 | - | $1.21B(-14.9%) | $6.75B(-9.1%) |
| Mar 2013 | - | $1.42B(-27.4%) | $7.42B(-9.2%) |
| Dec 2012 | $8.16B(-36.4%) | $1.95B(-9.7%) | $8.16B(+2.1%) |
| Sep 2012 | - | $2.17B(+15.2%) | $7.99B(-22.0%) |
| Jun 2012 | - | $1.88B(-13.3%) | $10.24B(-10.7%) |
| Mar 2012 | - | $2.17B(+21.5%) | $11.47B(-10.7%) |
| Dec 2011 | $12.84B(+7.0%) | $1.78B(-59.6%) | $12.84B(-5.6%) |
| Sep 2011 | - | $4.42B(+42.4%) | $13.59B(+16.1%) |
| Jun 2011 | - | $3.10B(-12.4%) | $11.71B(-0.5%) |
| Mar 2011 | - | $3.54B(+39.3%) | $11.77B(-2.0%) |
| Dec 2010 | $12.00B(+1.2%) | $2.54B(+0.4%) | $12.01B(+2.0%) |
| Sep 2010 | - | $2.53B(-20.0%) | $11.78B(-6.4%) |
| Jun 2010 | - | $3.16B(-16.3%) | $12.57B(+1.7%) |
| Mar 2010 | - | $3.78B(+63.5%) | $12.36B(+4.2%) |
| Dec 2009 | $11.86B(+18.6%) | $2.31B(-30.6%) | $11.86B(+1.7%) |
| Sep 2009 | - | $3.33B(+13.0%) | $11.66B(+5.2%) |
| Jun 2009 | - | $2.94B(-10.1%) | $11.09B(+3.0%) |
| Mar 2009 | - | $3.28B(+55.3%) | $10.76B(+7.6%) |
| Dec 2008 | $10.00B | $2.11B(-23.5%) | $10.00B(+9.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2008 | - | $2.76B(+5.3%) | $9.12B(+6.0%) |
| Jun 2008 | - | $2.62B(+4.1%) | $8.60B(+4.9%) |
| Mar 2008 | - | $2.52B(+105.1%) | $8.19B(+1.2%) |
| Dec 2007 | $8.09B(-1.5%) | $1.23B(-45.2%) | $8.09B(-1.9%) |
| Sep 2007 | - | $2.24B(+1.2%) | $8.25B(-1.1%) |
| Jun 2007 | - | $2.21B(-8.5%) | $8.34B(-3.7%) |
| Mar 2007 | - | $2.42B(+74.9%) | $8.66B(+5.4%) |
| Dec 2006 | $8.22B(+26.4%) | $1.38B(-40.6%) | $8.22B(+2.9%) |
| Sep 2006 | - | $2.33B(-8.1%) | $7.99B(+2.7%) |
| Jun 2006 | - | $2.53B(+28.1%) | $7.77B(+12.6%) |
| Mar 2006 | - | $1.98B(+71.5%) | $6.91B(+6.2%) |
| Dec 2005 | $6.50B(+43.0%) | $1.15B(-45.5%) | $6.50B(-1.8%) |
| Sep 2005 | - | $2.12B(+27.2%) | $6.62B(+16.6%) |
| Jun 2005 | - | $1.66B(+5.8%) | $5.68B(+12.1%) |
| Mar 2005 | - | $1.57B(+23.7%) | $5.07B(+10.7%) |
| Dec 2004 | $4.55B(+13.5%) | $1.27B(+8.4%) | $4.58B(+15.0%) |
| Sep 2004 | - | $1.17B(+11.4%) | $3.98B(+1.5%) |
| Jun 2004 | - | $1.05B(-3.0%) | $3.92B(+3.3%) |
| Mar 2004 | - | $1.08B(+60.8%) | $3.80B(-5.3%) |
| Dec 2003 | $4.01B(+0.0%) | $674.00M(-39.4%) | $4.01B(-0.8%) |
| Sep 2003 | - | $1.11B(+20.3%) | $4.04B(+4.5%) |
| Jun 2003 | - | $925.04M(-28.6%) | $3.87B(-3.5%) |
| Mar 2003 | - | $1.30B(+83.1%) | $4.00B(-0.0%) |
| Dec 2002 | $4.01B(-3.6%) | $707.26M(-24.6%) | $4.01B(-8.7%) |
| Sep 2002 | - | $937.74M(-11.9%) | $4.39B(-1.7%) |
| Jun 2002 | - | $1.06B(-18.0%) | $4.47B(+2.9%) |
| Mar 2002 | - | $1.30B(+19.0%) | $4.34B(+5.0%) |
| Dec 2001 | $4.16B(+4.4%) | $1.09B(+7.4%) | $4.14B(-1.0%) |
| Sep 2001 | - | $1.01B(+8.0%) | $4.18B(+2.1%) |
| Jun 2001 | - | $940.00M(-13.9%) | $4.09B(-1.1%) |
| Mar 2001 | - | $1.09B(-3.7%) | $4.14B(+4.0%) |
| Dec 2000 | $3.98B(+16.1%) | $1.13B(+22.0%) | $3.98B(+18.8%) |
| Sep 2000 | - | $928.53M(-6.0%) | $3.35B(+0.6%) |
| Jun 2000 | - | $987.45M(+5.9%) | $3.33B(-0.6%) |
| Mar 2000 | - | $932.80M(+85.1%) | $3.35B(-51.7%) |
| Dec 1999 | $3.43B(+41.3%) | $504.00M(-44.5%) | $6.94B(+332.0%) |
| Sep 1999 | - | $908.00M(-10.0%) | $1.61B(-47.0%) |
| Jun 1999 | - | $1.01B(-77.7%) | $3.03B(+12.0%) |
| Mar 1999 | - | $4.52B(-193.6%) | $2.71B(+350.0%) |
| Dec 1998 | $2.43B(+28.6%) | -$4.83B(-307.3%) | $601.10M(-41.2%) |
| Sep 1998 | - | $2.33B(+240.2%) | $1.02B(+29.2%) |
| Jun 1998 | - | $685.00M(-71.7%) | $791.55M(-66.9%) |
| Mar 1998 | - | $2.42B(-154.8%) | $2.39B(+5.9%) |
| Dec 1997 | $1.89B(+6.1%) | -$4.41B(-310.1%) | $2.26B(-40.9%) |
| Sep 1997 | - | $2.10B(-8.1%) | $3.82B(-5.3%) |
| Jun 1997 | - | $2.28B(0.0%) | $4.03B(+0.1%) |
| Mar 1997 | - | $2.28B(-180.2%) | $4.03B(+0.1%) |
| Dec 1996 | $1.78B(+69.1%) | -$2.85B(-223.1%) | $4.02B(+89.9%) |
| Sep 1996 | - | $2.31B(+1.5%) | $2.12B(+21.8%) |
| Jun 1996 | - | $2.28B(0.0%) | $1.74B(-1184.3%) |
| Mar 1996 | - | $2.28B(-147.9%) | -$160.41M(-62.0%) |
| Dec 1995 | $1.05B(-8.3%) | -$4.75B(-345.6%) | -$421.81M(-240.2%) |
| Sep 1995 | - | $1.94B(+411.0%) | $300.94M(+153.4%) |
| Jun 1995 | - | $378.70M(-81.2%) | $118.74M(-92.5%) |
| Mar 1995 | - | $2.02B(-150.1%) | $1.58B(+12.9%) |
| Dec 1994 | $1.15B(+0.8%) | -$4.03B(-329.9%) | $1.40B(-8.8%) |
| Sep 1994 | - | $1.75B(-4.6%) | $1.53B(+16.4%) |
| Jun 1994 | - | $1.84B(0.0%) | $1.32B(+7.2%) |
| Mar 1994 | - | $1.84B(-147.2%) | $1.23B(+7.8%) |
| Dec 1993 | $1.14B(+159.9%) | -$3.90B(-353.4%) | $1.14B(-77.4%) |
| Sep 1993 | - | $1.54B(-12.1%) | $5.03B(+44.0%) |
| Jun 1993 | - | $1.75B(0.0%) | $3.50B(+100.0%) |
| Mar 1993 | - | $1.75B | $1.75B |
| Dec 1992 | $438.32M(-68.4%) | - | - |
| Dec 1991 | $1.39B(+29.3%) | - | - |
| Dec 1990 | $1.07B | - | - |
FAQ
- What is AstraZeneca annual earnings before interest & taxes?
- What is the all time high annual EBIT for AstraZeneca?
- What is AstraZeneca annual EBIT year-on-year change?
- What is AstraZeneca quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for AstraZeneca?
- What is AstraZeneca quarterly EBIT year-on-year change?
- What is AstraZeneca TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for AstraZeneca?
- What is AstraZeneca TTM EBIT year-on-year change?
What is AstraZeneca annual earnings before interest & taxes?
The current annual EBIT of AZN is $10.43B
What is the all time high annual EBIT for AstraZeneca?
AstraZeneca all-time high annual earnings before interest & taxes is $12.84B
What is AstraZeneca annual EBIT year-on-year change?
Over the past year, AZN annual earnings before interest & taxes has changed by +$1.95B (+22.91%)
What is AstraZeneca quarterly earnings before interest & taxes?
The current quarterly EBIT of AZN is $2.10B
What is the all time high quarterly EBIT for AstraZeneca?
AstraZeneca all-time high quarterly earnings before interest & taxes is $4.52B
What is AstraZeneca quarterly EBIT year-on-year change?
Over the past year, AZN quarterly earnings before interest & taxes has changed by $0.00 (0.00%)
What is AstraZeneca TTM earnings before interest & taxes?
The current TTM EBIT of AZN is $10.43B
What is the all time high TTM EBIT for AstraZeneca?
AstraZeneca all-time high TTM earnings before interest & taxes is $13.59B
What is AstraZeneca TTM EBIT year-on-year change?
Over the past year, AZN TTM earnings before interest & taxes has changed by $0.00 (0.00%)